Date: 2012-07-17
Type of information: Fundraising
Company: Domain Therapeutics (France)
Investors: Seventure Partners (France) - SODIV (France) - AIRFI (Alsace Inter Regio Fonds d’Investissement) (France) - IP Growth - Auriga Partners (France) - Sam Eletr, the Chairman of the Board
Amount: € 2 million
Funding type: funding round
Planned used: Domain Therapeutics’ business model is currently transitioning from contract research activities for the pharmaceutical industry to collaborations and strategic alliances with existing clients and new partners. The new financing will support this evolution. During the past three years Domain has validated its innovative approach and is now strengthening its proprietary drug discovery platform DTect-All™ with complementary technologies to better respond to the G Protein Coupled Receptors (GPCR) market needs. In addition, some 30 high-throughput screening assays targeting high-potential GPCRs will soon be added to the Company’s existing portfolio. Domain Therapeutics is also moving forward with its internal research programs focusing on Alzheimer’s disease and depression (mGluR2 NAM), Parkinson’s disease (mGluR3 PAM - supported by the Michael J. Fox Foundation) and schizophrenia (undisclosed orphan GPCR –supported by a government grant).
Others: Domain Therapeutics, a biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G-Protein Coupled Receptors (GPCRs), has closed a € 2 million funding round. Half of the funds have been provided by a new investor, Seventure Partners and the other half has been committed by another new investor, SODIV, and Domain’s existing shareholders - AIRFI, IP Growth, Auriga and Sam Eletr, the Chairman of the Board.
Therapeutic area:
